One-time positioning of tumor "life gate", the full target genetic detection to help target immunotherapy.

(Health Times reporter Sun Huan)
" In the treatment of malignant tumors, traditional treatment sometimes can not achieve the desired results, and the emergence of immunotherapy and targeted therapy, changed the current treatment of all malignant tumors today, but want to achieve precision treatment, provided that the test is done. Referring to the current situation of cancer treatment, Yang Fan, chief of thoracic surgery at Peking University People's Hospital, said.
However, in real-world applications, the emergence of resistance of targeted drugs led to patients being forced to change drugs, in order to allow patients to benefit more from a single test, recently, and Ruigene released the large Panel genetic test "and all-an" series of new products - solid tumor target gene testing (654 genes). Unlike other testing products, the Large Panel Tumor Genetic Detection Product is a large package of genetic testing, which can locate the "life door" of tumors at once, helping patients to accurately use targeted drug therapy and immunotherapy.
tumor into the era of molecular division
the large Panel genetic test help lock the key
with the development of the times, tumor treatment in the last ten years has made a qualitative leap. Targeted drugs, immunotherapy has appeared one after another, so that some of the traditional treatment of poor effect of malignant tumor patients no longer helpless.
" it should be said that immunotherapy and targeted therapy have changed the face of all the treatment of malignant tumors today, some in the traditional treatment era, the treatment effect is very poor tumors, such as melanoma to the era of targeted treatment and immunotherapy, the face of treatment, the survival of patients, the patient's prognosis has opened a completely different chapter. Professor Yang Fan lamented.
With the deepening of understanding, people's understanding of tumors has changed. The appearance of tumors is attributed to genetic abnormalities, which cause cells to lose their normal regulation and become malignant cells with "lethality". At the same time, today's tumors are no longer considered a single disease, but are classified by genes and entered the age of molecular classification.lung adenocarcinoma molecular type
" as an example of lung cancer, early lung cancer is a disease, all long on the lungs of malignant tumors are called lung cancer, and then by tissue credit for small cells, non-small cells and divided into scaly cancer, adenocarcinoma, large cells. To this day, the type of lung cancer is no longer a combination of a tumor but a series of diseases. Professor Yang Fan pointed out that, like many other cancers, more molecular typed, so that the target type of genetic testing also increased, because the proportion of most genetic abnormalities is low, and even the proportion of many abnormal genes is less than 1%, at this time to accurately detect the mutation of lung cancer, need a "wide coverage", "high precision" gene detection products.
654 gene "wide-sata network"
to provide patients with more treatment options
the large Panel gene test ingons. This kind of genetic testing of the large package, can meet the clinical testing needs of targeted treatment, immunotherapy, so that patients do not have to repeat the test, but a test of a variety of genes, in the targeted treatment to help patients determine the type of tumor gene mutation, to achieve a key to open a lock accurate match.
" wide-cast nets to catch fish. In the case of colon cancer, the more targets covered are more likely to be detected, and the more patients will benefit from the test. Professor Yang Fan pointed out.
and Ruigene this product is so "wide-sating network", and Ruigene CEO Zhou Wei introduced, the product can detect 654 genes, including the current clinical drug-related genes 77, while comprehensive detection of 4 major types of variants, covering 6 categories of immunotherapy markers and 102 genes related to tumor genetic risk, including 200 MSI-related tumor pathways and high-frequency tumor mutations.
popularly speaking, the product can provide guidance for transcancer-targeted drugs, immunotherapy, chemotherapy in patients with advanced cancer, and can also reveal the family's genetic risk of tumors.
" tumor detection is not a hammer trade, some patients develop resistance after the need for genetic testing. But not all patients can provide many specimens clinically, which requires a one-stop shop to meet the needs of a wide range of coverage and provide patients with more treatment opportunities. Professor Yang Fan suggested that, of course, "extensive" is not all the needs of genetic testing, must also take into account accurate and sensitive, to be accurate not to miss, not to misjudge. The test results are "complete and accurate" and are the hope of genetic testing of tumors.
but it's worth noting that the larger the Panel, the higher the sequencing cost and the more expensive the product will be. For patients, choose which product to choose according to the condition, the overall economic situation to make considerations.
.